Cervical Cancer
📧 Sign up to get email alerts when something new happens for Cervical Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2026-04-23Clinical Trial Update: AssociatiNG Bevacizumab bEmarituzumab for GynecoLogIcal CAncer [Phase 1, Phase 2]
A clinical trial evaluating the combination of bevacizumab and bemarituzumab for gynecologic cancers (endometrial, ovarian, and cervical) ha…
-
CLINICAL_TRIALS withdrawal · 2026-03-03Clinical Trial Update: Comparison Of Cytology And Molecular Screening For Detecting Cervical Reactive Cellular Changes In General Population [NA]
A clinical trial comparing cytology and molecular screening for detecting cervical reactive cellular changes in the general population has b…
-
CLINICAL_TRIALS withdrawal · 2026-02-03Clinical Trial Update: Quality of Life Assessment of Radiotherapy in Recurrent Head and Neck Cancer [NA]
A clinical trial evaluating quality of life during radiotherapy for recurrent head and neck cancer has been withdrawn; the study also listed…
-
CLINICAL_TRIALS withdrawal · 2025-12-24Clinical Trial Update: STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma [Phase 1]
A Phase 1 study of STIL101 for injection across pancreatic ductal adenocarcinoma, colorectal cancer, renal cell carcinoma, cervical cancer, …
-
CLINICAL_TRIALS withdrawal · 2025-12-16Clinical Trial Update: A Clinical Study Comparing Chemotherapy Combined With PD-1 Inhibitor Versus Concurrent Chemoradiotherapy in Cervical Cancer Patients With Positive Lymph Nodes After Surgery: A Multicenter Randomized Controlled Clinical Trial [Phase 2, Phase 3]
A multicenter randomized trial comparing chemotherapy plus an unspecified PD-1 inhibitor to concurrent chemoradiotherapy in postoperative ce…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2025-05-29Clinical Trial Update: Evaluation of TRANSKRIP ® Plus Chemotherapy in Recurrent-Persistent Cervical Cancer [Phase 3]
A Phase 3 trial evaluating TRANSKRIP Plus Chemotherapy for recurrent-persistent cervical cancer has been withdrawn from the study.
-
CLINICAL_TRIALS withdrawal · 2025-03-19Clinical Trial Update: A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer
Pfizer's post-marketing surveillance study of Zirabev to assess safety and effectiveness in domestic cancer patients has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-03-07Clinical Trial Update: Community Outreach-based Study to Increase Cervical Cancer Screening Among Hispanic Women in Cleveland
A community outreach-based study aimed at increasing cervical cancer screening among Hispanic women in Cleveland has been withdrawn.
-
EMA withdrawal · 2024-10-24EMA Withdrawn: Onbevzi (bevacizumab) — Samsung Bioepis NL B.V.
The EMA has withdrawn the marketing authorization for Onbevzi (bevacizumab) by Samsung Bioepis NL B.V., across multiple cancer indications. …
-
CLINICAL_TRIALS withdrawal · 2024-09-20Clinical Trial Update: Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer. [Phase 2]
A Phase 2 trial evaluating VB10.16 alone or with atezolizumab for advanced cervical cancer has been withdrawn. No results have been posted.
-
CLINICAL_TRIALS withdrawal · 2022-10-05Clinical Trial Update: Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA) [Phase 3]
Phase 3 trial BRAVA comparing balstilimab to investigator’s choice chemotherapy in recurrent/metastatic cervical cancer has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2022-05-05Clinical Trial Update: A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer [Phase 3]
Phase III study evaluating HLX10 plus chemotherapy for advanced cervical cancer has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2021-11-17Clinical Trial Update: Pretherapeutic Paraaortic Lymphadenectomy in Women With Locally Advanced Cervical Cancer Versus Definitive Chemoradiotherapy [Phase 3]
A Phase 3 trial comparing pretherapeutic paraaortic lymphadenectomy versus definitive chemoradiotherapy in locally advanced cervical cancer …
-
CLINICAL_TRIALS withdrawal · 2017-11-29Clinical Trial Update: Erlotinib, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB-Stage IVA Cervical Cancer [Phase 1]
Phase 1 trial evaluating the combination of erlotinib, cisplatin, and radiation therapy for stage IB-IV cervical cancer; the study has been …
-
CLINICAL_TRIALS withdrawal · 2017-08-23Clinical Trial Update: Neoadjuvant Bevacizumab and Carboplatin Followed by Concurrent Bevacizumab, Carboplatin and Radiotherapy in the Primary Treatment of Cervix Cancer [Phase 2]
A Phase 2 trial evaluating neoadjuvant bevacizumab and carboplatin followed by concurrent bevacizumab, carboplatin, and radiotherapy for cer…
-
CLINICAL_TRIALS withdrawal · 2017-08-01Clinical Trial Update: Cyclooxygenase-2 Expression in Tissue Samples From Patients With a Normal Cervix, Cervical Intraepithelial Neoplasia, or Early Invasive Cervical Cancer
Wake Forest University Health Sciences sponsored a study evaluating cyclooxygenase-2 expression in cervical tissue from normal cervix throug…
-
CLINICAL_TRIALS withdrawal · 2017-07-02Clinical Trial Update: A Pilot, Open-label Study of 18F-Fluciclatide PET/CT Imaging in the Evaluation of Anti-angiogenic Therapy in Solid Tumors [Phase 1, Phase 2]
The trial evaluating 18F-Fluciclatide PET/CT imaging for anti-angiogenic therapy in solid tumors has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2017-04-20Clinical Trial Update: Phase II, Open Label, Non-randomized, Trial of BKM120 for Metastatic or Locally Advanced Cervical Cancer [Phase 2]
A Phase II, open-label, non-randomized trial of BKM120 (buparlisib) for metastatic or locally advanced cervical cancer has been withdrawn. T…
-
CLINICAL_TRIALS withdrawal · 2017-02-24Clinical Trial Update: The Potential for HPV Self-testing to Promote Participation in Cervical Screening [NA]
This update notes the withdrawal of a clinical trial evaluating HPV self-testing to promote participation in cervical screening.
-
CLINICAL_TRIALS withdrawal · 2016-12-15Clinical Trial Update: Docetaxel and Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Cervical Cancer [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating docetaxel with radiation therapy for stage II-IV cervical cancer has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2016-08-16Clinical Trial Update: Phase II Study of Pazopanib and Topotecan in Cervical Cancer [Phase 2]
Phase II trial of pazopanib in combination with topotecan for cervical cancer has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2016-05-13Clinical Trial Update: A Phase II Clinical Trial of Chemo-radiotherapy in Combination With INO-3112 in Patients With Locally Advanced Cervical Cancer [Phase 2]
Phase II trial of chemo-radiotherapy plus INO-3112 for locally advanced cervical cancer has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2016-02-25Clinical Trial Update: An Initial Feasibility Study to Integrate MRI Based Brachytherapy and CT/MR Fused INRT in Treatment of Advance Cervical Cancer [Phase 1]
Phase 1 feasibility trial of integrating MRI-based brachytherapy with CT/MR fused INRT for locally advanced cervical cancer was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2015-07-20Clinical Trial Update: Antibody Persistence for GlaxoSmithKline (GSK) Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) Administered in Healthy Adults and Adolescents, 6.5 Years After First Vaccination in the Primary Study [Phase 3]
A Phase 3 study evaluating long-term antibody persistence of GlaxoSmithKline's HPV-16/18 L1 VLP AS04 vaccine (GSK-580299) in healthy adults …
-
CLINICAL_TRIALS withdrawal · 2015-07-20Clinical Trial Update: Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus Vaccine (Cervarix™) When Co-administered With GSK Biologicals' Hepatitis A Vaccine (Havrix®) in Healthy Female Adolescents Aged 9-14 Years [Phase 3]
Phase 3 immunogenicity and safety study evaluating co-administration of Cervarix with Havrix in healthy girls aged 9-14, which has been with…